Table 7.

The Target Predictions of Imidazole Derivatives as Anti-Cancer

Compounds Codes	GPCR Ligand	Ion Channel Modulator	Kinase Inhibitor	Nuclear Receptor Ligand	Protease Inhibitor	Enzyme Inhibitor	Reported Target	Reference
Imidazole Derivatives as Anti-Cancer
C1	−0.10	−0.20	0.08	−0.41	−0.57	−0.33	Topoisomerase IIR catalytic inhibitors.	[9]
C2	−0.89	−2.07	−1.81	−1.61	−0.81	−1.39	ND	[10]
C3	0.23	0.16	0.61	−0.87	0.21	0.12	Focal Adhesion Kinase (FAK) inhibition.	[12]
C4	0.53	0.34	0.28	−0.05	0.10	0.41	ND	[14]
C5	−0.09	−0.14	−0.12	−0.62	−0.62	−0.02	Cyclin-dependent kinase 6 (CDK6) inhibition	[15]
C6	−0.20	−0.23	0.41	−0.59	−0.48	0.25	ND	[16]
C7	−0.13	−0.64	0.03	−0.46	−0.52	−0.18	ND	[17]
C8	−0.16	−0.27	0.13	−0.48	−0.33	0.06	Inhibit tubulin polymerization	[21]
C9	−0.35	−1.07	−0.69	−1.19	−0.48	−0.14	ND	[22]
C10	0.13	0.11	0.28	−0.03	−0.09	0.09	ND Possibly due to dimerized estrogen receptor	[18]
C11	0.32	0.30	0.51	−0.19	−0.24	0.31	c-MYC G-quadruplex DNA stabilizers	[19]
C12	0.18	−0.16	0.37	−0.45	−0.11	0.04	Aurora kinase inhibition	[20]
C13	0.12	−0.47	0.13	−0.30	−0.07	−0.07	Inhibit BRAFV600E kinase	[23]
C14	−0.28	−0.85	−0.34	−0.62	−0.34	−0.20	Inhibit GSK-3β	[24]
C15	0.35	0.16	0.20	−0.04	0.20	0.29	ND	[11]
C16	−0.86	−1.08	−1.15	−1.02	−1.16	−0.60	ND	[13]
C17	0.12	0.04	−0.15	−0.38	0.03	0.00	ND	[25]